海利爾(603639.SH):子公司製劑項目通過環保驗收
格隆匯3月30日丨海利爾(603639.SH)公佈,2022年3月30日,青島奧迪斯生物科技有限公司收到“年產10,000噸農用化學品製劑自動化生產線改造升級、23,000噸農用化學品製劑及肥料製造項目(一期)、7,000T水性化製劑項目竣工環境保護驗收意見”,該項目的性質、規模、地點、採用的生產工藝、防止污染、防止生態破壞的措施均未發生重大變動;項目實施過程中按照環評、批覆及環保要求落實了相關環保措施,建立了相應的環保管理制度,污染物排放達到國家相關排放標準。因此,該項目竣工環境保護驗收合格。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.